BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 2009;169:1104-12. [PMID: 19546410 DOI: 10.1001/archinternmed.2009.112] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Terrier B, Resche-Rigon M, Andres E, Bonnet F, Hachulla E, Marie I, Rosenthal E, Cacoub P; Groupe de Recherche sur les Anémies en Médecine Interne. Prevalence, characteristics and prognostic significance of anemia in daily practice. QJM 2012;105:345-54. [PMID: 22119918 DOI: 10.1093/qjmed/hcr230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
2 McMahon LP, MacGinley R; KHA-CARI. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology (Carlton) 2012;17:17-9. [PMID: 22044720 DOI: 10.1111/j.1440-1797.2011.01535.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
3 Finkelstein FO, Arsenault KL, Taveras A, Awuah K, Finkelstein SH. Assessing and improving the health-related quality of life of patients with ESRD. Nat Rev Nephrol 2012;8:718-24. [DOI: 10.1038/nrneph.2012.238] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
4 LaVallee C, Cronin P, Bansal I, Kwong WJ, Boccia R. Importance of Initial Complete Parenteral Iron Repletion on Hemoglobin Level Normalization and Health Care Resource Utilization: A Retrospective Analysis. Pharmacotherapy 2019;39:983-93. [PMID: 31411763 DOI: 10.1002/phar.2319] [Reference Citation Analysis]
5 Moist LM, Troyanov S, White CT, Wazny LD, Wilson J, Mcfarlane P, Harwood L, Sood MM, Soroka SD, Bass A, Manns BJ. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. American Journal of Kidney Diseases 2013;62:860-73. [DOI: 10.1053/j.ajkd.2013.08.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
6 Mazairac AH, de Wit GA, Penne EL, van der Weerd NC, de Jong B, Grooteman MP, van den Dorpel MA, Buskens E, Dekker FW, Nubé MJ, Ter Wee PM, Boeschoten EW, Bots ML, Blankestijn PJ; CONTRAST investigators. Changes in quality of life over time--Dutch haemodialysis patients and general population compared. Nephrol Dial Transplant 2011;26:1984-9. [PMID: 21051503 DOI: 10.1093/ndt/gfq680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
7 Berns JS. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?: . Current Opinion in Nephrology and Hypertension 2010;19:567-72. [DOI: 10.1097/mnh.0b013e32833c3cc7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Meira FS, Figueiredo AE, Zemiarcki J, Pacheco J, Poli-de-figueiredo CE, D'avila DO. Two Variable Sodium Profiles and Adverse Effects During Hemodialysis: A Randomized Crossover Study: Adverse Effects and Sodium Profiles. Therapeutic Apheresis and Dialysis 2010;14:328-33. [DOI: 10.1111/j.1744-9987.2009.00787.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
9 McClellan WM, Abramson J, Newsome B, Temple E, Wadley VG, Audhya P, McClure LA, Howard VJ, Warnock DG, Kimmel P. Physical and psychological burden of chronic kidney disease among older adults. Am J Nephrol 2010;31:309-17. [PMID: 20164652 DOI: 10.1159/000285113] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
10 Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, Agodoa IL. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant 2012;27:2418-25. [PMID: 22187314 DOI: 10.1093/ndt/gfr697] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
11 Kiefer MM, Ryan MJ. Primary Care of the Patient with Chronic Kidney Disease. Med Clin North Am 2015;99:935-52. [PMID: 26320040 DOI: 10.1016/j.mcna.2015.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Badve SV, Hawley CM, Johnson DW. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton) 2011;16:144-53. [PMID: 21272125 DOI: 10.1111/j.1440-1797.2010.01407.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
13 Friedman AJ, Chen Z, Ford P, Johnson CA, Lopez AM, Shander A, Waters JH, van Wyck D. Iron deficiency anemia in women across the life span. J Womens Health (Larchmt) 2012;21:1282-9. [PMID: 23210492 DOI: 10.1089/jwh.2012.3713] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
14 Handelman GJ, Kotanko P, Cisternas MG, Hoenich N, Usvyat L, Kuhlmann M, Levin NW. Hospitalization and mortality in hemodialysis patients: association with hemoglobin variability. Blood Purif 2013;35:247-57. [PMID: 23689318 DOI: 10.1159/000345338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Arantes LH Jr, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018;129:79-90. [PMID: 30097240 DOI: 10.1016/j.critrevonc.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ. An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis 2010;56:1050-61. [PMID: 20932621 DOI: 10.1053/j.ajkd.2010.07.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
17 Aguiar R, Pei M, Qureshi AR, Lindholm B. Health-related quality of life in peritoneal dialysis patients: A narrative review. Semin Dial 2019;32:452-62. [PMID: 30575128 DOI: 10.1111/sdi.12770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
18 de Goeij MCM, Meuleman Y, van Dijk S, Grootendorst DC, Dekker FW, Halbesma N; for the PREPARE-2 Study Group. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. Nephrology Dialysis Transplantation 2014;29:1391-8. [DOI: 10.1093/ndt/gft533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
19 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E, Sekigami T, Ogawa H, Matsui K. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial. Hypertens Res 2019;42:883-91. [PMID: 30664702 DOI: 10.1038/s41440-019-0210-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hoshino J, Muenz D, Zee J, Sukul N, Speyer E, Guedes M, Lopes AA, Asahi K, van Haalen H, James G, Dhalwani N, Pecoits-filho R, Bieber B, Robinson BM, Pisoni RL, Lopes A, Pecoits-filho R, Combe C, Jacquelinet C, Massy Z, Stengel B, Duttlinger J, Fliser D, Lonnemann G, Reichel H, Wada T, Yamagata K, Pisoni R, Robinson B, Calice da Silva V, Sesso R, Speyer E, Asahi K, Hoshino J, Narita I, Perlman R, Port F, Sukul N, Wong M, Young E, Zee J. Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD. Journal of Renal Nutrition 2020;30:404-14. [DOI: 10.1053/j.jrn.2019.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
22 Maoujoud O, Ahid S, Cherrah Y. The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. Int J Nephrol Renovasc Dis 2016;9:35-43. [PMID: 26966386 DOI: 10.2147/IJNRD.S96027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Mazairac AH, de Wit GA, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, Lévesque R, van den Dorpel MA, Nubé MJ, ter Wee PM, Blankestijn PJ, Bots ML. Clinical Performance Targets and Quality of Life in Hemodialysis Patients. Blood Purif 2012;33:73-9. [DOI: 10.1159/000334639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol 2012;7:354-7. [PMID: 22266571 DOI: 10.2215/CJN.11961111] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
25 Reardon G, Pandya N, Bailey RA. Falls in nursing home residents receiving pharmacotherapy for anemia. Clin Interv Aging 2012;7:397-407. [PMID: 23055706 DOI: 10.2147/CIA.S34789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS One 2017;12:e0172735. [PMID: 28249030 DOI: 10.1371/journal.pone.0172735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Alicic RZ, Tuttle KR. Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 2010;23:140-7. [DOI: 10.1111/j.1525-139x.2010.00700.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
28 AlKharboush H, Alshehri F, Alatwi I, Al Karni K, Alatawi A, Hamdan AM. The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients. Cureus 2020;12:e11895. [PMID: 33415047 DOI: 10.7759/cureus.11895] [Reference Citation Analysis]
29 Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernández-Moreno J, Llisterri-Caro JL, Mazón P, Montañés R, Morales-Olivas F, Muñoz-Torres M, de Pablos-Velasco P, de Santiago A, Sánchez-Celaya M, Suárez C, Tranche S. [Consensus document for the detection and management of chronic kidney disease]. Aten Primaria 2014;46:501-19. [PMID: 25288498 DOI: 10.1016/j.aprim.2014.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
30 Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011;6:845-855. [PMID: 21212421 DOI: 10.2215/cjn.06450710] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
31 Goldsmith D. 2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010;5:929-35. [PMID: 20413441 DOI: 10.2215/CJN.09131209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
32 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
33 Mazairac AH, Grooteman MP, Blankestijn PJ, Penne EL, van der Weerd NC, den Hoedt CH, van den Dorpel MA, Buskens E, Nubé MJ, ter Wee PM, de Wit GA, Bots ML; CONTRAST investigators. Differences in quality of life of hemodialysis patients between dialysis centers. Qual Life Res 2012;21:299-307. [PMID: 21633878 DOI: 10.1007/s11136-011-9942-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
34 Chan R, Brooks R, Steel Z, Heung T, Erlich J, Chow J, Suranyi M. The psychosocial correlates of quality of life in the dialysis population: a systematic review and meta-regression analysis. Qual Life Res 2012;21:563-80. [PMID: 21805367 DOI: 10.1007/s11136-011-9973-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
35 Martínez-castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernández-moreno J, Llisterri-caro JL, Mazón P, Montañés R, Morales-olivas F, Muñoz-torres M, de Pablos-velasco P, de Santiago A, Sánchez-celaya M, Suárez C, Tranche S. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Endocrinología y Nutrición 2014;61:e25-43. [DOI: 10.1016/j.endonu.2014.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Roger SD, Jassal SV, Woodward MC, Soroka S, Mcmahon LP. A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. Int Urol Nephrol 2014;46:469-75. [DOI: 10.1007/s11255-013-0512-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
37 Manns BJ, Tonelli M. The new FDA labeling for ESA--implications for patients and providers. Clin J Am Soc Nephrol 2012;7:348-53. [PMID: 22266575 DOI: 10.2215/CJN.09960911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
38 Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, Brookhart MA. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis. American Journal of Kidney Diseases 2016;67:271-82. [DOI: 10.1053/j.ajkd.2015.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
39 Perrone RD, Coons SJ, Cavanaugh K, Finkelstein F, Meyer KB. Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. Am J Kidney Dis 2013;62:1046-57. [PMID: 23988757 DOI: 10.1053/j.ajkd.2013.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
40 Al-Ageel NA, Al-Aqeel SA, Abanmy NO, Alwakeel JS, Sabry A, Alsaran KA. Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J 2012;20:85-91. [PMID: 23960781 DOI: 10.1016/j.jsps.2011.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
41 Martin ML, Patrick DL, Gandra SR, Bennett AV, Leidy NK, Nissenson AR, Finkelstein FO, Lewis EF, Wu AW, Ware JE Jr. Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia. Qual Life Res 2011;20:889-901. [PMID: 21161411 DOI: 10.1007/s11136-010-9812-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
42 Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet 2019;393:1417-27. [PMID: 30857647 DOI: 10.1016/S0140-6736(18)32562-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
43 Picon PD, Pribbernow SC, Prompt CA, Schacher SC, Antunes VV, Mentz BP, Oliveira FL, Souza CM, Schacher FC. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. Clinics (Sao Paulo) 2014;69:547-53. [PMID: 25141114 DOI: 10.6061/clinics/2014(08)08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Liu W, Li L, Zhang X, Dong H, Lu M. Efficacy and Safety of Veverimer in the Treatment of Metabolic Acidosis Caused by Chronic Kidney Disease: A Meta-analysis. Front Pharmacol 2021;12:643128. [PMID: 33995050 DOI: 10.3389/fphar.2021.643128] [Reference Citation Analysis]
45 Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Winkelmayer WC, van Biesen W, Crowe S, Kerr PG, Polkinghorne KR, Howard K, Pollock C, Hawley CM, Johnson DW, McDonald SP, Gallagher MP, Urquhart-Secord R, Craig JC; SONG-HD Collaboration. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials 2015;16:364. [PMID: 26285819 DOI: 10.1186/s13063-015-0895-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
46 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
49 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
50 Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernández-Moreno J, Llisterri-Caro JL, Mazón P, Montañés R, Morales-Olivas F, Muñoz-Torres M, de Pablos-Velasco P, de Santiago A, Sánchez-Celaya M, Suárez C, Tranche S. [Consensus document for the detection and management of chronic kidney disease]. Semergen 2014;40:441-59. [PMID: 25282133 DOI: 10.1016/j.semerg.2014.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
51 Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:153-9. [PMID: 20051850 DOI: 10.1097/MNH.0b013e328335f939] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
52 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
53 Tay J, Tinmouth A, Fergusson D, Allan D. Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials 2011;12:207. [PMID: 21936907 DOI: 10.1186/1745-6215-12-207] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
54 Testa U. Erythropoietic stimulating agents. Expert Opinion on Emerging Drugs 2010;15:119-38. [DOI: 10.1517/14728210903499273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
55 Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet 2019;394:396-406. [PMID: 31248662 DOI: 10.1016/S0140-6736(19)31388-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 9.3] [Reference Citation Analysis]
56 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
57 Wu IW, Hsu KH, Sun CY, Tsai CJ, Wu MS, Lee CC. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study. Nephrol Dial Transplant 2014;29:1719-27. [PMID: 24714415 DOI: 10.1093/ndt/gfu061] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
58 Finkelstein FO, van Nooten F, Wiklund I, Trundell D, Cella D. Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health Qual Life Outcomes 2018;16:111. [PMID: 29855366 DOI: 10.1186/s12955-018-0933-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
59 Garrido P, Ribeiro S, Fernandes J, Vala H, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Santos-Silva A, Reis F. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. Int J Mol Sci 2015;17:E28. [PMID: 26712750 DOI: 10.3390/ijms17010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]